Table 1.
Interventions in clinical trials for long-COVID
| Company | Intervention | Target | Clinical stage |
|---|---|---|---|
| Amgen | Ivabradine (HCN channel blocker) | POTS | Off-label use |
| Ampio Pharmaceuticals | Cyclized peptide derived from aspartyl-alanyl diketopiperazine isolated from human serum | DAMPs induced by viruses | Phase 1 |
| CytoDyn | Leronlimab (monoclonal against CCR5) | Inflammation | Phase 2 |
| GioCOV, a subsidiary of Giostar | Allogeneic mesenchymal stem cells | Inflammation | Compassionate use (FDA) |
| AIM ImmunoTech | Rintatolimod (poly(I):poly(C12U)) | Virus | Phase 3 |
| PureTech | Deuterated pirfenidone | Pulmonary fibrosis | Phase 2 |
| Synairgen (Southampton, UK) | Inhaled interferon beta-1a | COPD | Phase 3 |